Therapeutic Interventions for Tone Abnormalities in Cerebral Palsy

被引：9
作者：
Tilton A.H. [1 ]
机构：
[1] Louisiana State University Health, Sciences Center, New Orleans
来源：
NeuroRX | 2006年 / 3卷 / 2期
关键词：
botulinum toxin; Cerebral palsy; intrathecal baclofen; orthopedic surgery; selective dorsal rhizotomy; spasticity;
D O I：
10.1016/j.nurx.2006.01.008
中图分类号：
学科分类号：
摘要：
Summary: Cerebral palsy (CP) is a common cause of movement disorders in children. The upper motor neuron syndrome of CP leads to several types of muscle overactivity, including spasticity. Reduction of muscle overactivity may be an important treatment goal, to improve comfort, care, and active function and to prevent future musculoskeletal complications. After a comprehensive team evaluation, a treatment plan is generated. Treatments may include physical and occupational therapy, oral medications, botulinum toxin and/or phenol injections, intrathecal baclofen, selective dorsal rhizotomy, and orthopedic surgery. Successful and early prevention of contracture may reduce the need for later corrective surgery. © 2006 The American Society for Experimental NeuroTherapeutics, Inc.
引用
收藏
页码：217 / 224
页数：7
相关论文
共 67 条
  • [1] Surveillance of cerebral palsy in Europe. a collaboration of cerebral palsy surveys and registers, Dev Med Child Neurol, 42, pp. 816-824, (2000)
  • [2] Pharoah P.O., Platt M.J., Cooke T., The changing epidemiology of cerebral palsy, Arch Dis Child Fetal Neonatal Ed, 75, (1996)
  • [3] Bax M., Goldstein M., Rosenbaum P., Leviton A., Paneth N., Dan B., Jacobsson B., Damiano D., Proposed definition and classification of cerebral palsy, April 2005, Dev Med Child Neurol, 47, pp. 571-576, (2005)
  • [4] Nelson K.B., Ellenberg J.H., Epidemiology of cerebral palsy, Adv Neurol, 19, pp. 421-435, (1978)
  • [5] Sanger T.D., Delgado M.R., Gaebler-Spira D., Hallett M., Mink J.W., Classification and definition of disorders causing hypertonia in childhood, Pediatrics, 111, (2003)
  • [6] Mayer N.H., Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motor neuron lesion, Spasticity. etiology, evaluation, management, and the role of botulinum toxin, pp. 1-15, (2002)
  • [7] Russman B.S., Tilton A., Gormley Jr. M.E., Cerebral palsy. a rational approach to a treatment protocol, and the role of botulinum toxin in treatment, Muscle Nerve Suppl, 6, (1997)
  • [8] Lance J.W., Symposium synopsis, Spasticity. disordered motor control, pp. 485-494, (1980)
  • [9] Mayer N.H., Herman R.M., Phenomenology of muscle overactivity in the upper motor neuron syndrome, Muscle overactivity in the upper motor neuron syndrome. the role of oral medications, a focus on dantrolene sodium, pp. 1-25, (2004)
  • [10] Bohannon R.W., Smith M.B., Interrater reliablity of a modified Ashworth scale of muscle spasticity, Phys Ther, 67, pp. 206-207, (1986)
1234567